Metrics as of 10/17/2026, 04:03 AM (Berlin time), refresh in progress.
EyePoint Pharmaceuticals Stock
EyePoint Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jay S. Duker
- Employees
- 214
- Market cap
- $251 M
- IPO
- 27/01/2005
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert…
EyePoint Pharmaceuticals stock: price history
1D
-4.8%
1W
-12.1%
1M
-13.3%
6M
-80.0%
YTD
-83.6%
1Y
-74.1%
2Y
-73.5%
5Y
-73.9%
10Y
-87.1%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~29% stronger price swings than usual
EyePoint Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
EyePoint Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of ophthalmic therapies for treating various eye diseases. The business model relies primarily on licensing and partnership agreements as well as the sale of products such as ILUVIEN, YUTIQ, and DEXYCU. In addition to the commercial offering of existing therapeutics, the company invests in a pipeline of new drug candidates for the treatment of retinal diseases. Business operations extend across the United States, China, and the United Kingdom.
- Revenue model
- Licensing
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Bausch + Lomb CorporationDescriptionAsk the agents about EyePoint Pharmaceuticals
Analyst assessment of EyePoint Pharmaceuticals
PRICE TARGET LOW
US$4.00
CONSENSUS
US$18.29
MEDIAN
US$8.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
13
BUY
7
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 02/09/2026
EyePoint Pharmaceuticals stock metrics
P/E
-0.8
P/B
1.55
EV/EBITDA
-0.55
RETURN ON EQUITY
-56.8%
NET MARGIN
-18,633.1%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.3%
FLOAT SHARES
80,711,078
AVG. DAILY VOLUME (30D)
3,203,433
Insider transactions (SEC)
Elston George
Elston George
Elston George
Elston George
Zaderej Karen L.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.8%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about EyePoint Pharmaceuticals stock
What does EyePoint Pharmaceuticals do?
EyePoint Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jay S. Duker, the company employs around 214 people.
The IPO was on 27/01/2005; the stock trades on NASDAQ under the ticker EYPT.
What do analysts say about EyePoint Pharmaceuticals stock?
20 analysts rate the stock, the consensus is Buy (as of 02/09/2026).
The average price target is US$18.29, ranging from US$4.00 to US$40.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does EyePoint Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does EyePoint Pharmaceuticals pay a dividend?
No, EyePoint Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to EyePoint Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get EyePoint Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess EyePoint Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.